Atlas Trials

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Clinical trial NCT03075553 · TERMINATED

Trial details

NCT number
NCT03075553
Sponsor
Mayo Clinic
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Blastic Plasmacytoid Dendritic Cell NeoplasmHepatosplenic T-Cell LymphomaHTLV-1 InfectionNK-Cell Lymphoma, UnclassifiablePrimary Systemic Anaplastic Large Cell Lymphoma, ALK-NegativeRecurrent Adult T-Cell Leukemia/LymphomaRecurrent Anaplastic Large Cell LymphomaRecurrent Angioimmunoblastic T-cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Mycosis FungoidesRefractory Adult T-Cell Leukemia/LymphomaRefractory Anaplastic Large Cell Lymphoma
Start date
2017-05-17
Primary completion
2019-05-29
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.